These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17239011)

  • 41. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis.
    Calabrese M; De Stefano N; Atzori M; Bernardi V; Mattisi I; Barachino L; Morra A; Rinaldi L; Romualdi C; Perini P; Battistin L; Gallo P
    Arch Neurol; 2007 Oct; 64(10):1416-22. PubMed ID: 17923625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.
    Suhy J; Rooney WD; Goodkin DE; Capizzano AA; Soher BJ; Maudsley AA; Waubant E; Andersson PB; Weiner MW
    Mult Scler; 2000 Jun; 6(3):148-55. PubMed ID: 10871825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis.
    Sastre-Garriga J; Ingle GT; Chard DT; Ramió-Torrentà L; McLean MA; Miller DH; Thompson AJ
    Arch Neurol; 2005 Apr; 62(4):569-73. PubMed ID: 15824254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis.
    Mesaros S; Rovaris M; Pagani E; Pulizzi A; Caputo D; Ghezzi A; Bertolotto A; Capra R; Falautano M; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2008 Sep; 65(9):1223-30. PubMed ID: 18779427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study.
    Pulizzi A; Rovaris M; Judica E; Sormani MP; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2007 Aug; 64(8):1163-8. PubMed ID: 17698707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study.
    Dehmeshki J; Chard DT; Leary SM; Watt HC; Silver NC; Tofts PS; Thompson AJ; Miller DH
    J Neurol; 2003 Jan; 250(1):67-74. PubMed ID: 12527995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fractal dimension and white matter changes in multiple sclerosis.
    Esteban FJ; Sepulcre J; de Mendizábal NV; Goñi J; Navas J; de Miras JR; Bejarano B; Masdeu JC; Villoslada P
    Neuroimage; 2007 Jul; 36(3):543-9. PubMed ID: 17499522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased citrullinated glial fibrillary acidic protein in secondary progressive multiple sclerosis.
    Nicholas AP; Sambandam T; Echols JD; Tourtellotte WW
    J Comp Neurol; 2004 May; 473(1):128-36. PubMed ID: 15067723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Connecting white matter injury and thalamic atrophy in clinically isolated syndromes.
    Henry RG; Shieh M; Amirbekian B; Chung S; Okuda DT; Pelletier D
    J Neurol Sci; 2009 Jul; 282(1-2):61-6. PubMed ID: 19394969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study.
    Schmierer K; Altmann DR; Kassim N; Kitzler H; Kerskens CM; Doege CA; Aktas O; Lünemann JD; Miller DH; Zipp F; Villringer A
    Mult Scler; 2004 Apr; 10(2):182-7. PubMed ID: 15124765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study.
    Rovaris M; Bozzali M; Iannucci G; Ghezzi A; Caputo D; Montanari E; Bertolotto A; Bergamaschi R; Capra R; Mancardi GL; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2002 Sep; 59(9):1406-12. PubMed ID: 12223026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive impairment and structural brain damage in benign multiple sclerosis.
    Rovaris M; Riccitelli G; Judica E; Possa F; Caputo D; Ghezzi A; Bertolotto A; Capra R; Falautano M; Mattioli F; Martinelli V; Comi G; Filippi M
    Neurology; 2008 Nov; 71(19):1521-6. PubMed ID: 18815387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.
    Misu T; Fujihara K; Kakita A; Konno H; Nakamura M; Watanabe S; Takahashi T; Nakashima I; Takahashi H; Itoyama Y
    Brain; 2007 May; 130(Pt 5):1224-34. PubMed ID: 17405762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of progressive multiple sclerosis with cyclophosphamide].
    Zephir H; De Seze J; Sénéchal O; Stojkovic T; Ferriby D; Deliss B; Dubus B; Verier A; Hautecoeur P; Vermersch P
    Rev Neurol (Paris); 2002 Jan; 158(1):65-9. PubMed ID: 11938324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis.
    Khaleeli Z; Sastre-Garriga J; Ciccarelli O; Miller DH; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1076-82. PubMed ID: 17287235
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?
    Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F
    Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of tight junction molecules in blood vessels of germinal matrix, cerebral cortex, and white matter.
    Ballabh P; Hu F; Kumarasiri M; Braun A; Nedergaard M
    Pediatr Res; 2005 Oct; 58(4):791-8. PubMed ID: 16189211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions.
    Koning N; Bö L; Hoek RM; Huitinga I
    Ann Neurol; 2007 Nov; 62(5):504-14. PubMed ID: 17879969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis.
    Pousinis P; Ramos IR; Woodroofe MN; Cole LM
    Metabolites; 2020 Sep; 10(9):. PubMed ID: 32911763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.